MannKind reported $-67.2M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Adma Biologics USD 408.21M 17.88M Jun/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Halozyme Therapeutics USD 143.54M 76.09M Jun/2026
Insmed USD 757.49M 52.64M Jun/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
MacroGenics USD 42.87M 21.68M Jun/2026
MannKind USD -67.2M 8M Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Novavax USD -190.71M 45.94M Jun/2026
Novo Nordisk DKK 33.81B 169.25B Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
Xencor USD 503.23M 12.4M Jun/2026